News & Research

Related Q&A

DILAUDID-HP SUMMARY

DILAUDID-HP® INJECTION 10 mg/ml (hydromorphone hydrochloride)CS-II

DILAUDID (hydromorphone hydrochloride), a hydrogenated ketone of morphine, is an opioid analgesic.

DILAUDID-HP is indicated for the relief of moderate-to-severe pain in opioid-tolerant patients who require larger than usual doses of opioids to provide adequate pain relief. Because DILAUDID-HP contains 10 mg of hydromorphone hydrochloride per mL, a smaller injection volume can be used than with other parenteral opioid formulations. Discomfort associated with the intramuscular or subcutaneous injection of an unusually large volume of solution can therefore be avoided.

Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. [2010.06]CONCLUSIONS: These results provide evidence for the efficacy and safety of hydromorphone ER in opioid-tolerant patients with chronic moderate-to-severe LBP. Potential limitations include the shortened dose-conversion/titration phase, limiting the daily allowable dose of hydromorphone ER to 64 mg, and the allowance of limited rescue medication throughout the entire double-blind phase. Other trial design elements such as the use of an enrichment phase and the inclusion of only opioid tolerant patients may limit the generalizability of these results.

Comparison of Side Effects of Morphine and Hydromorphone PCA [Completed]
Both morphine and hydromorphone are pain medications commonly used after surgery. It is
thought at our institution that hydromorphone causes less side effects but this has not been
studied. We propose to treat our patients with either morphine or hydromorphone and
determine how much nausea, vomiting, and itching they have with each drug

Study of Respiratory Depression When Using a Hydromorphone Pain Protocol [Recruiting]
This is a study about the efficiency and safety of a 1mg+1mg hydromorphone pain management
protocol for the treatment of moderate to sever pain in the Emergency Department.
Appropriate patients 60 years and older who present with a condition that causes moderate to
severe pain, according to the attending physician's judgment, in which the physician would
order the use of parenteral analgesia will be enrolled in one of two study arms, "1+1"
versus usual care group. 1+1 patients will receive 1mg hydromorphone followed by another 1mg
after 15 minutes if pain persists. Usual care group patients will have pain treated per the
discretion of the attending physician. Respiratory status, vital signs, and pain scores will
be monitor to assess the efficiency of pain control as well as the safety of pain medicine
administration in terms of respiratory depression.